Please ensure Javascript is enabled for purposes of website accessibility

Why Illumina Stock Is Sinking Today

By Keith Speights – Sep 21, 2020 at 12:15PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors are skeptical about the company's latest acquisition.

What happened

Shares of Illumina (ILMN 4.56%) are sinking today, down 6.7% as of 11:48 a.m. EDT, after the genomic-sequencing specialist announced that it plans to acquire GRAIL for $8 billion.

So what

Illumina actually founded GRAIL in 2016 but later spun out the company as a stand-alone entity. GRAIL is focused on the development of liquid biopsies: blood tests that detect cancer by identifying fragments of DNA separated from tumor cells.

DNA double helix hovering over an outstretched palm

Image source: Getty Images.

GRAIL is targeting a total addressable market that could grow to $75 billion by 2035. So why were investors not happy with Illumina's acquisition news? Probably because of the price tag of the deal.

Earlier this month, GRAIL filed for an initial public offering (IPO). Its valuation as it prepared to go public was estimated to be around $1.9 billion. Illumina will spend four times that amount to get a company that doesn't have any products on the market yet and that has no steady source of revenue. The fact that Illumina is investing so much to get a company that it already owned just a few years ago makes the deal even harder to swallow for investors.

Now what

The price that Illumina is paying for GRAIL won't matter over the long run -- if GRAIL is successful in developing and marketing liquid biopsy products. GRAIL hopes to launch its first product, multicancer early detection test Galleri, next year for laboratory use only. With Illumina's shares trading at more than 42 times expected earnings, the company will need to deliver some good news soon to convince investors the healthcare stock is worth buying at its premium valuation.

Keith Speights owns shares of Illumina. The Motley Fool owns shares of and recommends Illumina. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Nearly 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Illumina Stock Quote
Illumina
ILMN
$218.08 (4.56%) $9.51

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
349%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.